Scholarlink

<p>The history behind the proof, and acceptance, of neutral lipid domains in the plasma membranes of transformed and cancer cells is noteworthy. Not only for the controversy, but because this membrane structure has become a hallmark for women at risk for breast cancer. The membrane model, proposed in 1988 to contain isotropically tumbling domains, made up of triglycerides, cholesterol, and cholesterol ester, was not verified until 2010 by a team of Danish scientists. In the intervening 22 years, focus in this area was on the fluid lipid bilayer and the presence of intracellular droplets. The proof of neutral lipid domains in the plasma membranes, mobile on the MR timescale, involved chemists, physicists, pathologists, and surgeons from Australia and Canada and finally Denmark. Today, the appearance of these neutral lipid domains is the first of a series of changes that are diagnostic for risk of breast cancer and considered by some as a point of clinical pharmaceutical intervention for those at risk of developing cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Controversial membrane structure, independently verified after 22 years, is diagnostic and prognostic for cancer risk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Carolyn Mountford,
  • Tyrone Humphries

摘要

The history behind the proof, and acceptance, of neutral lipid domains in the plasma membranes of transformed and cancer cells is noteworthy. Not only for the controversy, but because this membrane structure has become a hallmark for women at risk for breast cancer. The membrane model, proposed in 1988 to contain isotropically tumbling domains, made up of triglycerides, cholesterol, and cholesterol ester, was not verified until 2010 by a team of Danish scientists. In the intervening 22 years, focus in this area was on the fluid lipid bilayer and the presence of intracellular droplets. The proof of neutral lipid domains in the plasma membranes, mobile on the MR timescale, involved chemists, physicists, pathologists, and surgeons from Australia and Canada and finally Denmark. Today, the appearance of these neutral lipid domains is the first of a series of changes that are diagnostic for risk of breast cancer and considered by some as a point of clinical pharmaceutical intervention for those at risk of developing cancer.